Abiopharma

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Astrana Health, Inc. to Participate in Upcoming Investor Conference

Butterfly Network, Inc. - Butterfly Network to Extend its Proprietary 3D Imaging Capabilities to Butterfly Garden Developers

Johnson & Johnson - Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

Elanco Animal Health Inc. - Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Edgewise Therapeutics - Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter